Global Finance Observer
SEE OTHER BRANDS

Your best source on finance and banking news from the world

Portnoy Law Firm Announces Class Action on Behalf of Nutex Health, Inc. Investors

LOS ANGELES, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nutex Health, Inc., (“Nutex” or the "Company") (NASDAQ: NUTX) investors off a class action on behalf of investors that bought securities between August 8, 2024 and August 14, 2025, inclusive (the “Class Period”). Nutex investors have until October 21, 2025 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/nutex-health-inc/. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

On July 22, 2025, Blue Orca Capital (“Blue Orca”) issued a short report on Nutex. The Blue Orca report alleges, among other things, that Nutex faces litigation risk due to its relationship with HaloMD, a third-party vendor that was recently sued for engaging in a “coordinated fraudulent scheme” to take millions from insurance companies on behalf of healthcare billing clients. Following publication of the Blue Orca report, Nutex’s stock price fell $11.18 per share, or 10.05%, to close at $100.01 per share on July 22, 2025.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions